多参数MRI在前列腺癌局灶激光消融后长期监测中的作用
该回顾性研究分析了54例低中危前列腺癌患者局灶激光消融后的多参数MRI表现,早期随访(中位4个月)和晚期随访(中位49个月)分别有30例和42例。结果显示晚期MRI上治疗区强化或弥散受限与活检阳性相关,而早期MRI检测复发能力有限。
要点
- 消融后治疗区常见边界不清的瘢痕伴或不伴萎缩。
- 晚期随访中,治疗区强化或弥散受限提示复发可能。
- 早期随访MRI对复发检测敏感性低,PSA变化与活检结果无关。
关键影像表现/征象
- 治疗区最常见表现为边界不清的瘢痕,伴或不伴萎缩。
- 早期随访中,活检为临床显著前列腺癌(≥GG2或≥6 mm GG1)的4例患者中仅1例在治疗区显示强化或弥散受限。
- 晚期随访中,治疗区强化者活检阳性5/8(63%),弥散受限者活检阳性5/6(83%)。
诊断标准与关键数值
- 临床显著前列腺癌定义为活检≥GG2或≥6 mm GG1。
- 晚期随访治疗区强化预测活检阳性的比例为5/8(63%),弥散受限预测活检阳性的比例为5/6(83%)。
临床应用与阅片要点
- 局灶激光消融后晚期随访应关注治疗区强化和弥散受限,提示可能的复发。
- 早期随访MRI阴性不能排除复发,需结合后续随访。
- PSA变化与活检结果无关,不应单独依据PSA判断复发。
局限性
- 样本量小。
- 回顾性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Determine the multiparametric magnetic resonance imaging (mpMRI) appearance of the prostate following focal laser ablation (FLA) for PCa and to identify imaging characteristics associated with recurrent disease.
METHODS: Retrospective analysis of patients who underwent FLA for low-intermediate risk PCa between 2010 and 2014 was performed. Early (median 4 months) and late mpMRI (median 49 months) follow-up were qualitatively assessed for T2-weighted, dynamic contrast enhanced (DCE) and diffusion weighted imaging (DWI) appearances and also compared to corresponding PSA values and biopsy results.
RESULTS: 55 cancers were treated in 54 men (mean age 61.0 years). Early mpMRI was performed in 30 (54.5%) patients while late follow-up mpMRI in 42 (84%). Ill-defined scarring with and without atrophy at the treatment site were the most common appearances. In patients with paired MRI and biopsy, one of four patients with clinically significant PCa on biopsy (≥GG2 or≥6 mm GG1) showed hyperenhancement or restricted diffusion at early follow-up. At late follow-up, positive biopsies were seen in 5/8 (63%) cases with hyperenhancement and 5/6 (83%) cases with restricted diffusion at the treatment site. PSA change was not associated with biopsy results at either time point.
CONCLUSION: mpMRI is able to document the morphological and temporal changes following focal therapy. It has limited ability to detect recurrent disease in early months following treatment. Late-term mpMRI is sensitive at identifying patients with recurrent disease. Small sample size is, however, a limitation of the study.
ADVANCES IN KNOWLEDGE: Implementing MRI in follow-up after FT may be useful in predicting residual or recurrent PCa and therefore provide reliable outcome data.
引用
- Paxton M, Barbalat E, Perlis N, et al. Role of multiparametric MRI in long-term surveillance following focal laser ablation of prostate cancer. Br J Radiol. 2021. PMID: 34324385. doi:10.1259/bjr.20210414
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。